871.3500 -1.35 (-0.15%)
NSE Jul 10, 2025 15:09 PM
Volume: 347.2K
 

871.35
-0.15%
Axis Direct
Q1 revenue growth (10% YoY) was in line, but EBITDA declined 34% YoY (37% below our expectations) on lower gross margin of 50.2% (down 260 bps YoY). Gross margin declined due to (1) price erosion in key partnership products in US; delay in its key approvals
Strides Pharma Scien.. has an average target of 1524.50 from 2 brokers.
More from Strides Pharma Science Ltd.
Recommended